EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structural Mapping of Surveillance Data Reveals Conservation of NNI Binding Site in RSV L Protein

Ruchin Patel, Edward Murray, Debbie D Nahas, Mahdieh Yazdani iD, Brett Ambler iD, Nicholas Murgolo iD, John A Howe

Pathogens · 2026

DOI: 10.3390/pathogens15010085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2026. Verfasst von Ruchin Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, NJ 07065, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Respiratory Syncytial Virus, Human, Viral Proteins. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infections (LRTIs) and infant mortality worldwide. Despite recent advances in prophylactic interventions, effective therapeutics for active RSV infection are still lacking. Small molecule non-nucleoside inhibitors (NNIs) targeting the RSV L protein, particularly its polyribonucleotidyltransferase (PRNTase) domain, represent a promising antiviral strategy. Here, we evaluate the genetic variability of the PRNTase domain and the binding pocket of two NNIs, MRK-1 and MRK-2, to assess the potential for preexisting resistance. A comprehensive analysis of 28,140 RSV L protein sequences from NCBI Virus and GISAID EpiRSV databases revealed low overall variability within the PRNTase domain and near-complete conservation of the MRK-1/2 binding pocket. Resistance-associated mutations identified through in vitro dose-escalation studies localized to this pocket but were absent in global sequence datasets. These findings support the PRNTase domain as a genetically stable and viable target for NNI-based RSV therapeutics and suggest a low likelihood of preexisting resistance among circulating strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsRespiratory Syncytial Virus, HumanViral ProteinsBinding SitesHumansDrug Resistance, ViralRespiratory Syncytial Virus InfectionsMutationProtein BindingModels, Molecular

Stichwörter der Autor:innen

MRK-1NNIPRNTaseRSVpolymeraseresistancesurveillance

Substanzen

Antiviral AgentsViral Proteins

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, NJ 07065, USA.

ORCID-Profile: Mahdieh Yazdani, Brett Ambler, Nicholas Murgolo

Förderung

  • Merck Sharp & Dohme LLC

Zitieren

APA

Patel, R., Murray, E., Nahas, D. D., Yazdani, M., Ambler, B., Murgolo, N., & Howe, J. A. (2026). Structural Mapping of Surveillance Data Reveals Conservation of NNI Binding Site in RSV L Protein. Pathogens. https://doi.org/10.3390/pathogens15010085

Vancouver

Patel R, Murray E, Nahas DD, Yazdani M, Ambler B, Murgolo N, et al. Structural Mapping of Surveillance Data Reveals Conservation of NNI Binding Site in RSV L Protein. Pathogens. 2026. doi:10.3390/pathogens15010085

BibTeX
@article{Patel2026,
  author = {Patel, Ruchin and Murray, Edward and Nahas, Debbie D and Yazdani, Mahdieh and Ambler, Brett and Murgolo, Nicholas and Howe, John A},
  title = {Structural Mapping of Surveillance Data Reveals Conservation of NNI Binding Site in RSV L Protein},
  journal = {Pathogens},
  year = {2026},
  doi = {10.3390/pathogens15010085}
}
Kostenlos starten →